These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 29687320)

  • 1. Tyrosine Kinase Inhibitors in the Treatment of Chronic-Phase CML: Strategies for Frontline Decision-making.
    Kennedy JA; Hobbs G
    Curr Hematol Malig Rep; 2018 Jun; 13(3):202-211. PubMed ID: 29687320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring.
    Jabbour E; Kantarjian H
    Am J Hematol; 2016 Feb; 91(2):252-65. PubMed ID: 26799612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving Outcomes in Chronic Myeloid Leukemia Over Time in the Era of Tyrosine Kinase Inhibitors.
    Chopade P; Akard LP
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):710-723. PubMed ID: 30093283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C; Bianchini M; Bengió R; Larripa I
    Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring.
    Jabbour E; Kantarjian H
    Am J Hematol; 2018 Mar; 93(3):442-459. PubMed ID: 29411417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selecting the best frontline treatment in chronic myeloid leukemia.
    Yilmaz M; Abaza Y; Jabbour E
    Curr Hematol Malig Rep; 2015 Jun; 10(2):145-57. PubMed ID: 25921387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia.
    Caldemeyer L; Akard LP
    Leuk Lymphoma; 2016 Dec; 57(12):2739-2751. PubMed ID: 27562641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors.
    Lipton JH; Bryden P; Sidhu MK; Huang H; McGarry LJ; Lustgarten S; Mealing S; Woods B; Whelan J; Hawkins N
    Leuk Res; 2015 Jan; 39(1):58-64. PubMed ID: 25466286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase.
    García-Gutiérrez V; Breccia M; Jabbour E; Mauro M; Cortes JE
    J Hematol Oncol; 2022 Jul; 15(1):90. PubMed ID: 35818053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
    Abbott BL
    Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.
    Stansfield L; Hughes TE; Walsh-Chocolaad TL
    Ann Pharmacother; 2013 Dec; 47(12):1703-11. PubMed ID: 24396109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bosutinib for the treatment of chronic myeloid leukemia.
    Doan V; Wang A; Prescott H
    Am J Health Syst Pharm; 2015 Mar; 72(6):439-47. PubMed ID: 25736937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic myeloid leukemia: First-line drug of choice.
    Jabbour E
    Am J Hematol; 2016 Jan; 91(1):59-66. PubMed ID: 26769227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.
    Yun S; Vincelette ND; Segar JM; Dong Y; Shen Y; Kim DW; Abraham I
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e85-94. PubMed ID: 27101984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase.
    Rosti G; Castagnetti F; Gugliotta G; Palandri F; Baccarani M
    Crit Rev Oncol Hematol; 2012 May; 82(2):159-70. PubMed ID: 21565522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors.
    Sasaki K; Kantarjian HM; Jain P; Jabbour EJ; Ravandi F; Konopleva M; Borthakur G; Takahashi K; Pemmaraju N; Daver N; Pierce SA; O'Brien SM; Cortes JE
    Cancer; 2016 Jan; 122(2):238-48. PubMed ID: 26479889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.
    Wong SF; Mirshahidi H
    Ann Pharmacother; 2011 Jun; 45(6):787-97. PubMed ID: 21672900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
    Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
    Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Shamroe CL; Comeau JM
    Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.